MSB

3.21%

$1.13 mesoblast limited

Ann: Mesoblast Type A Meeting with FDA, page-56

First 56 Last

Share
Profile

Follow
Bigdaddio

146 Posts.

16

21/09/23

13:30

Post #: 69957751
Share

Originally posted by bedger: ↑

Contrary to many of the posts above I believe there is actually some real inconsistency here. Krause very clearly said in the recent post CRL conference that the FDA did not question efficacy:

"one of the significant positive indicators from the CRL - is that the CRL did not question the efficacy of the product as demonstrated in GvHD001, (which was the case for the previous CRL )" (Krause, 31 Aug 2023)

But then in this update:

"FDA noted that the lack of a suitable potency assay for the RYONCIL product used during the Phase 3 trial MSB-GVHD001 for the pediatric acute GVHD indication has prevented the trial from being considered an adequate study for the purpose of demonstrating substantial evidence of effectiveness required for a marketing approval."

If they didn't accept the potency assay, then they didn't in fact accept the efficacy as demonstrated by GVHD0001.

Perhaps I am wrong, but I think Silviu and Krause, are loudly here setting out the inconsistencies they are dealing with from the FDA themselves, for all too see, and showing all how they are arguing with the FDA on the validity of the potency assay and adding ever more data to back their claim and refute the contentions of the FDA, which they are showing as inconsistent and are picking away at.

"FDA indicated its willingness to consider Mesoblast’s proposed registrational trial design in adults, subject to agreement on the suitability of the potency assay for the product to be used in adults."

Clearly they are making some difficult progress on the potency assays with the FDA, both past used and those going forward and can't jeopardize that too much by too loudly pointing out FDA inconsistency, which has been shown innumerable times in other treatment decisions/processing by the FDA.

(happy be corrected by more informed MSB posters - not the peanut brigade)

Expand

Agreed - mega piss take going on here.

Just reread the BLA resubmission announcement from 1Feb which states MSB submitted new “validated potency assays” for the product used in the 54 patience study.

MSB Price at posting: 37.0¢ Sentiment: Hold Disclosure: Held
7 Upvote

0 Great analysis

Reply

Top Stories

NAM

ACCC seeks Olam divestments before it can buy Namoi Cotton

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

DEG

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

KAL

KalGold rolls out detailed aeromagnetic survey across Pinjin project

The market's shrugged at China's stimulus measures all year. Why is this one different?

STK

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

The winners & losers on market if negative gearing were gone

ESR

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

There are more pages in this discussion • 519 more messages in this thread...

First 56 Last

Add MSB (ASX) to my watchlist

(20min delay)
Last $1.13		Change 0.035(3.21%)		Mkt cap ! $1.284B

Open	High	Low	Value	Volume
$1.09	$1.13	$1.07	$3.910M	3.535M

Buyers (Bids)

No.	Vol.	Price($)
2	27197	$1.11

Sellers (Offers)

Price($)	Vol.	No.
$1.13	43578	3

View Market Depth

No.	Vol.	Price($)
4	31763	1.100
2	33264	1.090
2	18897	1.085
2	18926	1.080
1	18000	1.075

Price($)	Vol.	No.
1.130	23400	3
1.135	1090	1
1.140	65000	4
1.145	64500	3
1.150	92314	9

Last trade - 16.10pm 27/09/2024 (20 minute delay)

MSB (ASX) Chart

Ann: Mesoblast Type A Meeting with FDA, page-56

ACCC seeks Olam divestments before it can buy Namoi Cotton

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

KalGold rolls out detailed aeromagnetic survey across Pinjin project

The market's shrugged at China's stimulus measures all year. Why is this one different?

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

The winners & losers on market if negative gearing were gone

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Mesoblast Type A Meeting with FDA, page-56

Top Stories

ACCC seeks Olam divestments before it can buy Namoi Cotton

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

KalGold rolls out detailed aeromagnetic survey across Pinjin project

The market's shrugged at China's stimulus measures all year. Why is this one different?

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

The winners & losers on market if negative gearing were gone

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News